MAPT and Alzheimer disease: The dynamic association of the dual proteinopathy is a crucial factor in developing new disease modifying drugs for AD for they may not only explain that the dominance of tau as a possible reason for the relative lack of efficiency in anti-Aβ trials, but also indicate the importance of targeting the dual modulation of tau and Aβ.